AUA 2022

Outcomes of Robotic, Open Cystectomy Compared in Bladder Cancer

The number of days alive and out of the hospital within the first 90 days of surgery is greater for robot-assisted surgery, but the clinical significance of the findings unclear.

PSA Bounce vs Biochemical Recurrence After Prostate Cancer SBRT Probed

Study reveals factors that could distinguish PSA bounce from biochemical recurrence after stereotactic body radiation therapy for prostate cancer.

PSA Screening for Prostate Cancer Beneficial, Especially for Black Men

In all studied scenarios, PSA screening appeared more favorable for Black men than for the general population.

Robotic Partial Nephrectomy Outcomes Worse When PSMs Are Present

Positive surgical margins in patients undergoing robotic partial nephrectomy for renal tumors are associated with adverse oncologic outcomes, a study revealed.

Prostate Cancer Upgrading on AS Linked to Perineural Invasion

The presence of perineural invasion in a prostate biopsy has important implications for active surveillance.

Neoadjuvant Axitinib May Enable Partial Nephrectomy in Complex Renal Tumors

An interim analysis suggests that axitinib given to patients with complex clear cell renal cell carcinoma tumors significantly reduces tumor size and complexity.

Study: Confirmatory Prostate Biopsies Still Needed Despite Upfront MRI

New findings challenge recommendations from the European Association of Urology.

Predictors of Recurrence After RNU for Low-Grade UTUC

The findings may inform surveillance strategies and improve treatment outcomes.

Black vs White Race Tied to Worse Survival in Renal Cell Carcinoma

While socioeconomic disparities are evident, survival differences between racial groups persist after RCC diagnosis.

Negative MRI in Active Surveillance Often Predicts Stable Prostate Cancer

Some patients with a negative mpMRI while on prostate cancer active surveillance may be able to defer biopsy, according to investigators.

Post-RC Radiation Does Not Up Survival in Locally Advanced Bladder Cancer

Further studies are needed to evaluate oncologic outcomes after postoperative radiation therapy.

ICIs May Improve mRCC Outcomes in Cytoreductive Nephrectomy Cases

Immune checkpoint inhibitors may be more beneficial than tyrosine kinase inhibitors for patients undergoing cytoreductive nephrectomy for metastatic renal cell carcinoma.

Use of 5-ARIs May Decrease Bladder Cancer Risk

A study examined bladder cancer risk and mortality among nearly 100,000 men from Ontario, Canada, who received 5-alpha reductase inhibitors.

Prostate Cancer Upgrading Risk in Active Surveillance Does Not Differ by Race

Active surveillance appears to be a safe treatment option for low- and very low-risk prostate cancer, regardless of race, according to investigators.

UTUC in Octogenarians Frequently Managed Without Surgery

Approximately one-quarter of patients aged 80 years or older with upper tract urothelial carcinoma are managed expectantly, data show.

Metastatic Prostate Cancer Survival Improved in Wake of Treatment Advances

Following the approval of cabazitaxel in 2010, there are now an unprecedented number of life-prolonging therapies for men with metastatic disease.

Prostate, Bladder Cancer Care Delays Common During Pandemic

Study characterized patient-reported delays in care of prostate cancer and bladder cancer at the national level.

Prostate Cancer Grade Migration Documented

Grade group 1 prostate cancers declined as a proportion of all prostate cancers.